Pathophysiology, Genetics & Diagnostic Criteria

Question	Answer
1. What is the basic genetic and molecular defect in Beta-Thalassemia Major?	Autosomal recessive disorder caused by over 300 different mutations (predominantly point mutations) in the HBB gene on chromosome $11p15.5$, leading to absent ($\beta^0$) or severely reduced ($\beta^+$) synthesis of $\beta$-globin chains of adult hemoglobin ($\text{HbA} = \alpha_2\beta_2$). - Pathophysiological Core: Unpaired, excess $\alpha$-globin chains precipitate inside developing erythroid precursors in the bone marrow, forming toxic crystalline inclusion bodies (hemichromes). This triggers reactive oxygen species, membrane damage, and apoptosis of $>80-90\%$ of erythroid precursors (Massive Ineffective Erythropoiesis), combined with severe peripheral extravascular hemolysis in the spleen.
2. Why does Beta-Thalassemia Major NOT manifest at birth?	In the fetus and newborn infant, the predominant hemoglobin is Fetal Hemoglobin ($\text{HbF} = \alpha_2\gamma_2$), which utilizes $\gamma$-globin chains rather than $\beta$-chains. Around 3 to 6 months of age, the physiological gene switch from $\gamma$-globin to $\beta$-globin expression takes place. When $\beta$-chain synthesis fails to occur, severe microcytic hypochromic anemia and ineffective erythropoiesis become clinically apparent between 6 to 12 months of life.
3. Explain the pathogenesis of "Chipmunk Facies" and the "Hair-on-End" radiological sign.	Driven by severe tissue hypoxia, massive renal erythropoietin secretion drives a 20- to 30-fold expansion of erythropoietic bone marrow. - Chipmunk Facies: Marrow hypertrophy expands within the facial and cranial bones, resulting in marked frontal bossing, prominent parietal eminences, depressed nasal bridge, elevated malar eminences, and overgrowth of the maxilla causing dental malocclusion and protruding upper incisors. - Hair-on-End Sign (Skull X-ray): Extreme widening of the diploic space with cortical thinning causes the bone trabeculae between the inner and outer tables to orient perpendicularly to the skull contour, resembling hairs standing on end.
4. What are the classical findings on Hemoglobin HPLC in Beta-Thalassemia Major?	- HbF ($\alpha_2\gamma_2$): Markedly elevated at $60\% - 95\%$ (diagnostic hallmark). - HbA ($\alpha_2\beta_2$): Completely absent in homozygous $\beta^0/\beta^0$, or severely reduced ($<10-15\%$) in $\beta^0/\beta^+$. - HbA2 ($\alpha_2\delta_2$): Variable ($1.5-3.5\%$). - Parental HPLC Screening: Essential for confirmation — both parents show elevated $\text{HbA}_2 > 3.5\%$ (diagnostic of heterozygous Beta-Thalassemia Minor / Trait).
5. VIVA TRAP: Can a high Reticulocyte Count rule out Thalassemia Major?	In thalassemia major, the raw reticulocyte count is often mildly elevated ($3-5\%$), but this is inappropriately low for the life-threatening severity of the anemia (e.g., for an Hb of 4-5 g/dL). Pathophysiological Reason: Massive intramedullary apoptosis destroys erythroid precursors before they can mature into reticulocytes (ineffective erythropoiesis), so few reticulocytes ever reach the peripheral bloodstream.

Transfusion Protocol & Iron Chelation

Question	Answer
6. Detail the "Hypertransfusion Regimen" for Thalassemia Major. What is the target pre-transfusion Hemoglobin?	- Core Goal: Maintain pre-transfusion Hemoglobin strictly between $9.5$ and $10.5\text{ g/dL}$ (post-transfusion Hb $13.5-14.0\text{ g/dL}$). - Scientific Rationale: 1) Completely shuts off endogenous ineffective erythropoiesis (prevents skeletal deformities and extramedullary bone expansion). 2) Suppresses massive hepatosplenomegaly and hypersplenism. 3) Prevents anemic cardiomegaly and high-output heart failure. 4) Promotes normal linear somatic growth, pubertal maturation, and physical activity. - Blood Specification: Transfuse Leukocyte-Depleted (leukofiltered) Packed Red Blood Cells (PRBC), phenotype-matched for Rh (D, C, c, E, e) and Kell antigens, NAT-screened. - Dose & Frequency: $10-15\text{ mL/kg}$ PRBCs infused over 3–4 hours every 3 to 4 weeks.
7. When should Iron Chelation Therapy be initiated? What are the available chelators?	- Initiation Criteria: Initiated when Serum Ferritin exceeds $>1,000\text{ ng/mL}$, or after the child has received $10-20$ PRBC transfusions (approximately 2–3 years of age). - Oral First-Line Chelator: - Deferasirox (DFX): $20-40\text{ mg/kg/day}$ once daily orally on an empty stomach. Monitor monthly serum creatinine, urine UPCR, and LFTs. - Alternative / Combination Chelators: - Deferiprone (DFP): Oral $75-100\text{ mg/kg/day}$ divided tid; highly lipid-soluble, enters cardiomyocytes readily (superior cardiac iron chelation). Requires weekly Absolute Neutrophil Count (ANC) monitoring due to $1-2\%$\ risk of fatal agranulocytosis! - Deferoxamine (DFO / Desferal): Subcutaneous infusion $30-50\text{ mg/kg/day}$ over 8–12 hours via portable pump 5–7 nights/week.
8. VIVA TRAP: What are the toxicities of Deferasirox, Deferiprone, and Deferoxamine?	- Deferasirox: Renal tubular toxicity (Fanconi-like syndrome, elevated creatinine, proteinuria), hepatic toxicity, gastrointestinal ulcers/bleeding. - Deferiprone: Agranulocytosis / neutropenia, arthropathy/joint swelling, gastrointestinal upset, hepatotoxicity. - Deferoxamine: Sensorineural high-frequency hearing loss, retinal pigmentary retinopathy, growth retardation/metaphyseal dysplasia, and susceptibility to fatal Yersinia enterocolitica sepsis (iron-chelator complex acts as a siderophore for Yersinia).
9. What are the indications for Splenectomy in Thalassemia Major?	Splenectomy should be deferred ideally until $>5-6\text{ years}$ of age to minimize overwhelming post-splenectomy sepsis (OPSS). Indications: 1) Annual transfusion requirement exceeding $>200-220\text{ mL/kg/year}$ of PRBCs (indicates accelerated splenic clearance). 2) Symptomatic hypersplenism with worsening cytopenias (leukopenia, thrombocytopenia). 3) Massive splenomegaly causing mechanical discomfort, early satiety, or high risk of traumatic splenic rupture. Mandatory Pre-requisites: Immunize with Pneumococcal conjugate (PCV13) + polysaccharide (PPSV23), Meningococcal conjugate (MenACWY), and H. influenzae type b (Hib) at least 2-4 weeks prior, followed by lifelong daily oral Penicillin V prophylaxis.
10. Counter-Question Chain: "What is the only proven curative therapy for Thalassemia Major?"	1) Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): The only widely established curative therapy, with best outcomes using an HLA-identical matched sibling donor (MSD). 2) Pesaro Risk Stratification (Classes I, II, III): Based on 3 variables: hepatomegaly $>2\text{ cm}$, portal fibrosis on liver biopsy, and inadequate chelation history. Class I patients have $>90\%$ disease-free survival. 3) Novel Curative Options: Gene therapy / Gene editing using autologous CD34+ cells: Betibeglogene autotemcel (lentiviral vector $\beta$-globin addition) and Exagamglogene autotemcel (Casgevy) (CRISPR-Cas9 gene editing of BCL11A enhancer reactivating endogenous HbF).